For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Submits Application for Approval of CS-866AZ Antihypertensive Combination Drug in Japan

Tokyo, December 11, 2008 - DAIICHI SANKYO COMPANY, LIMITED today announced that it has submitted an application for manufacturing and marketing approval to the Japanese Ministry of Health, Labour and Welfare for CS-866AZ, which it developed as a hypertension treatment.

CS-866AZ is a combination drug of the long-acting calcium channel blocker azelnidipine (Calblock® jointly researched and developed by DAIICHI SANKYO and its partner Ube Industries, Ltd., and the high affinity AT1 subtype angiotensin II receptor antagonist olmesartan medoxomil (Olmetec®Benicar®, developed by DAIICHI SANKYO.

In clinical trials, CS-866AZ showed superior results compared to monotherapy with azelnidipine or olmesartan medoxomil. While azelnidipine and olmesartan medoxomil have been popular treatment options, DAIICHI SANKYO believes CS-866AZ will provide new treatment options for patients with hypertension in Japan.